Evaluation of Idiopathic Choroidal Neovascularization with Indocyanine Green Angiography in Patients Undergoing Bevacizumab Therapy
Purpose. To examine the clinical implications of change in choroidal neovascularization (CNV) size on indocyanine green (ICG) angiography in subjects with idiopathic CNV undergoing bevacizumab therapy. Methods. The charts of subjects with an idiopathic CNV treated by a modified PRN regimen with intr...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2015/642624 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850227582851612672 |
|---|---|
| author | Ryan B. Rush Sloan W. Rush |
| author_facet | Ryan B. Rush Sloan W. Rush |
| author_sort | Ryan B. Rush |
| collection | DOAJ |
| description | Purpose. To examine the clinical implications of change in choroidal neovascularization (CNV) size on indocyanine green (ICG) angiography in subjects with idiopathic CNV undergoing bevacizumab therapy. Methods. The charts of subjects with an idiopathic CNV treated by a modified PRN regimen with intravitreal bevacizumab over a 12-month period were retrospectively reviewed. Results. There were 34 subjects included in the analysis. Baseline CNV sizes of less than 1.0 mm2 on ICG angiography correlated with complete CNV resolution (P=0.0404), fewer injections delivered (P=0.0002), and better Snellen visual acuity (P=0.0098) at 12 months. Subjects that experienced a 33% or more reduction in CNV size on ICG angiography at 2 months had complete CNV resolution (P=0.0047) and fewer injections (P<0.0001) at 12 months compared to subjects that did not experience a 33% or more reduction in CNV size on ICG angiography at 2 months. Conclusions. Smaller baseline CNV size on ICG angiography resulted in better visual acuity and fewer injections at 12 months, and a reduction of 33% or more in CNV size after 2 months may predict a better clinical course in subjects with idiopathic CNV undergoing bevacizumab therapy. |
| format | Article |
| id | doaj-art-206c959228ce4b4ab9f9aad22cee5cd5 |
| institution | OA Journals |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-206c959228ce4b4ab9f9aad22cee5cd52025-08-20T02:04:48ZengWileyJournal of Ophthalmology2090-004X2090-00582015-01-01201510.1155/2015/642624642624Evaluation of Idiopathic Choroidal Neovascularization with Indocyanine Green Angiography in Patients Undergoing Bevacizumab TherapyRyan B. Rush0Sloan W. Rush1Southwest Retina Specialists, 7411 Wallace Boulevard, Amarillo, TX 79106, USAPanhandle Eye Group, 7400 Fleming Avenue, Amarillo, TX 79106, USAPurpose. To examine the clinical implications of change in choroidal neovascularization (CNV) size on indocyanine green (ICG) angiography in subjects with idiopathic CNV undergoing bevacizumab therapy. Methods. The charts of subjects with an idiopathic CNV treated by a modified PRN regimen with intravitreal bevacizumab over a 12-month period were retrospectively reviewed. Results. There were 34 subjects included in the analysis. Baseline CNV sizes of less than 1.0 mm2 on ICG angiography correlated with complete CNV resolution (P=0.0404), fewer injections delivered (P=0.0002), and better Snellen visual acuity (P=0.0098) at 12 months. Subjects that experienced a 33% or more reduction in CNV size on ICG angiography at 2 months had complete CNV resolution (P=0.0047) and fewer injections (P<0.0001) at 12 months compared to subjects that did not experience a 33% or more reduction in CNV size on ICG angiography at 2 months. Conclusions. Smaller baseline CNV size on ICG angiography resulted in better visual acuity and fewer injections at 12 months, and a reduction of 33% or more in CNV size after 2 months may predict a better clinical course in subjects with idiopathic CNV undergoing bevacizumab therapy.http://dx.doi.org/10.1155/2015/642624 |
| spellingShingle | Ryan B. Rush Sloan W. Rush Evaluation of Idiopathic Choroidal Neovascularization with Indocyanine Green Angiography in Patients Undergoing Bevacizumab Therapy Journal of Ophthalmology |
| title | Evaluation of Idiopathic Choroidal Neovascularization with Indocyanine Green Angiography in Patients Undergoing Bevacizumab Therapy |
| title_full | Evaluation of Idiopathic Choroidal Neovascularization with Indocyanine Green Angiography in Patients Undergoing Bevacizumab Therapy |
| title_fullStr | Evaluation of Idiopathic Choroidal Neovascularization with Indocyanine Green Angiography in Patients Undergoing Bevacizumab Therapy |
| title_full_unstemmed | Evaluation of Idiopathic Choroidal Neovascularization with Indocyanine Green Angiography in Patients Undergoing Bevacizumab Therapy |
| title_short | Evaluation of Idiopathic Choroidal Neovascularization with Indocyanine Green Angiography in Patients Undergoing Bevacizumab Therapy |
| title_sort | evaluation of idiopathic choroidal neovascularization with indocyanine green angiography in patients undergoing bevacizumab therapy |
| url | http://dx.doi.org/10.1155/2015/642624 |
| work_keys_str_mv | AT ryanbrush evaluationofidiopathicchoroidalneovascularizationwithindocyaninegreenangiographyinpatientsundergoingbevacizumabtherapy AT sloanwrush evaluationofidiopathicchoroidalneovascularizationwithindocyaninegreenangiographyinpatientsundergoingbevacizumabtherapy |